| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Laboratoire d’Immunologie Cellulaire, Institut Gustave-Roussy, Villejuif, France; and
Centre d’Etudes et de Recherche en Virologie et Immunologie, Hôpital La Pitié-Salpétrière, Paris, France
The lymphocyte activation gene-3 (LAG-3) molecule is a T cell activation Ag closely related to CD4 at the gene and protein levels. We investigated whether LAG-3 itself may down-regulate the immune response by interfering with TCR signaling. The binding of Ab to the LAG-3 molecule followed by cross-linking (XL) inhibits cell proliferation and cytokine secretion in response to CD3XL on activated T cells. LAG-3XL-induced down-regulation is associated with functional unresponsiveness, as well as with high CD25 expression levels and reversion by exogenous IL-2. It is also associated with a down-modulation of CD3/TCR complex expression. At the biochemical level, LAG-3XL inhibits calcium response to CD3 stimulation. This inhibition is observed with different LAG-3- and CD3-specific mAbs on condition that the two receptors are cross-linked together. Finally, the capping of CD3 was shown to induce cocapping of LAG-3 molecules. Together, these results show that CD3/TCR complex-associated LAG-3 molecules can play an active role in negatively regulating the CD3/TCR activation pathway. They ultimately suggest that LAG-3 is an inhibitory receptor in activated T lymphocytes.
This article has been cited by other articles:
|
|
 |
|
  C. J. Workman, Y. Wang, K. C. El Kasmi, D. M. Pardoll, P. J. Murray, C. G. Drake, and D. A. A. Vignali LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis J. Immunol., February 15, 2009; 182(4): 1885 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Li, M. VanRoey, F. Triebel, and K. Jooss Lymphocyte Activation Gene-3 Fusion Protein Increases the Potency of a Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Clin. Cancer Res., June 1, 2008; 14(11): 3545 - 3554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Liang, C. Workman, J. Lee, C. Chew, B. M. Dale, L. Colonna, M. Flores, N. Li, E. Schweighoffer, S. Greenberg, et al. Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II J. Immunol., May 1, 2008; 180(9): 5916 - 5926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Casati, C. Camisaschi, L. Novellino, A. Mazzocchi, F. Triebel, L. Rivoltini, G. Parmiani, and C. Castelli Human Lymphocyte Activation Gene-3 Molecules Expressed by Activated T Cells Deliver Costimulation Signal for Dendritic Cell Activation J. Immunol., March 15, 2008; 180(6): 3782 - 3788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Oberle, N. Eberhardt, C. S. Falk, P. H. Krammer, and E. Suri-Payer Rapid Suppression of Cytokine Transcription in Human CD4+CD25 T Cells by CD4+Foxp3+ Regulatory T Cells: Independence of IL-2 Consumption, TGF-beta, and Various Inhibitors of TCR Signaling J. Immunol., September 15, 2007; 179(6): 3578 - 3587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Brignone, C. Grygar, M. Marcu, K. Schakel, and F. Triebel A Soluble Form of Lymphocyte Activation Gene-3 (IMP321) Induces Activation of a Large Range of Human Effector Cytotoxic Cells J. Immunol., September 15, 2007; 179(6): 4202 - 4211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bayry, F. Triebel, S. V. Kaveri, and D. F. Tough Human Dendritic Cells Acquire a Semimature Phenotype and Lymph Node Homing Potential through Interaction with CD4+CD25+ Regulatory T Cells J. Immunol., April 1, 2007; 178(7): 4184 - 4193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Gandhi, E. Lambley, J. Duraiswamy, U. Dua, C. Smith, S. Elliott, D. Gill, P. Marlton, J. Seymour, and R. Khanna Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients Blood, October 1, 2006; 108(7): 2280 - 2289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Casati, C. Camisaschi, F. Rini, F. Arienti, L. Rivoltini, F. Triebel, G. Parmiani, and C. Castelli Soluble Human LAG-3 Molecule Amplifies the In vitro Generation of Type 1 Tumor-Specific Immunity. Cancer Res., April 15, 2006; 66(8): 4450 - 4460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Workman and D. A. A. Vignali Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223) J. Immunol., January 15, 2005; 174(2): 688 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Li, C. J. Workman, S. M. Martin, and D. A. A. Vignali Biochemical Analysis of the Regulatory T Cell Protein Lymphocyte Activation Gene-3 (LAG-3; CD223) J. Immunol., December 1, 2004; 173(11): 6806 - 6812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Workman, K. J. Dugger, and D. A. A. Vignali Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-3 J. Immunol., November 15, 2002; 169(10): 5392 - 5395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Andreae, F. Piras, N. Burdin, and F. Triebel Maturation and Activation of Dendritic Cells Induced by Lymphocyte Activation Gene-3 (CD223) J. Immunol., April 15, 2002; 168(8): 3874 - 3880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. El mir and F. Triebel A Soluble Lymphocyte Activation Gene-3 Molecule Used as a Vaccine Adjuvant Elicits Greater Humoral and Cellular Immune Responses to Both Particulate and Soluble Antigens J. Immunol., June 1, 2000; 164(11): 5583 - 5589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hannier and F. Triebel The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes Int. Immunol., November 1, 1999; 11(11): 1745 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-N. Avice, M. Sarfati, F. Triebel, G. Delespesse, and C. E. Demeure Lymphocyte Activation Gene-3, a MHC Class II Ligand Expressed on Activated T Cells, Stimulates TNF-{alpha} and IL-12 Production by Monocytes and Dendritic Cells J. Immunol., March 1, 1999; 162(5): 2748 - 2753. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
